<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917357</url>
  </required_header>
  <id_info>
    <org_study_id>QVX-V-D001</org_study_id>
    <nct_id>NCT01917357</nct_id>
  </id_info>
  <brief_title>A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject</brief_title>
  <official_title>A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem® DTwP-HepB-Hib) in Uniject™ With Quinvaxem® Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to show that vaccination with three doses of Quinvaxem presented in Uniject
      is not inferior to vaccination with three doses of Quinvaxem presented in single dose vials,
      with respect to protection against all antibodies (anti-hepatitis B surface antibodies,
      anti-polyribosyl ribitol phosphate (PRP), anti-diphtheria, anti-tetanus and anti-Bordetella
      pertussis) one (1) month after completion of the 6-10-14 week vaccination course.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-PRP Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-hepatitis B Surface Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-diphtheria Toxoid Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-tetanus Toxoid Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-B. Pertussis Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Hepatitis B</condition>
  <condition>Haemophilus Infections</condition>
  <arm_group>
    <arm_group_label>Quinvaxem in Uniject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quinvaxem in single dose vials</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quinvaxem in Uniject</intervention_name>
    <arm_group_label>Quinvaxem in Uniject</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quinvaxem in single dose vials</intervention_name>
    <arm_group_label>Quinvaxem in single dose vials</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female between, and including, 42 and 64 days of age at the time of the
             first vaccination

          -  Written informed consent obtained from parents/legal guardians of the subject

          -  Free of obvious health problems as established by medical history and/or clinical
             examination before entering the study

          -  HepB vaccination at birth (within 48 hours)

          -  Available for all scheduled study visits

        Exclusion Criteria:

          -  Use of any investigational drug or any investigational vaccine in the 30 days
             preceding the first dose of study vaccine, or their planned use during the study
             period and safety follow-up

          -  Planned administration of a vaccine not foreseen by the Study Protocol

          -  Known or suspected impairment of immune function, known HIV-positivity; actively
             receiving immunosuppressive therapy, or in receipt of systemic immunosuppressive
             therapy in the one month prior to study entry (note: inhaled and topical steroids are
             allowed)

          -  Administration of parenteral immunoglobulin preparation and/or blood products since
             birth

          -  Previous vaccination against Hib and/or DTP

          -  History of anaphylaxis, or any serious vaccine reaction, or hypersensitivity to any
             vaccine component or to products containing mercury compounds, such as thiomersal

          -  Clinically significant acute infection

          -  Clinically significant acute illness

          -  Any condition that, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives

          -  Participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>64 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria RZ Capeding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Tropical Medicine (RITM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>July 12, 2014</last_update_submitted>
  <last_update_submitted_qc>July 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Immunisation</keyword>
  <keyword>Virus</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Haemophilus Influenzae</keyword>
  <keyword>Immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetanus Antitoxin</mesh_term>
    <mesh_term>Diphtheria Antitoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

